InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
16,954.40
(
-0.17%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
84.00
(
0.54%
)
Bitcoin
57,411.12
(
-1.42%
)

Replies to post #15620 on Momenta Pharmaceuticals, Inc. (MNTA)

Replies to #15620 on Momenta Pharmaceuticals, Inc. (MNTA)

DewDiligence

06/08/16 11:28 AM

#15623 RE: DewDiligence #15620

Correction to #msg-123102901: The number of patients in the phase-2 portion of the Necuparanib trial is approximately 150 (not 180). Source: today’s GS webcast.